Close menu




July 22nd, 2021 | 09:41 CEST

American Water Works, Memiontec, Rio Tinto: Solid Company operating in a booming region

  • Investments
Photo credits: pixabay.com

Water is a precious commodity - a fact now remembered since the recent flood disaster in parts of Rhineland-Palatinate and North Rhine-Westphalia. People without access to clean water are more likely to suffer from infectious diseases. What is only an issue here for a few weeks after natural disasters is sadly commonplace in other regions. It is not without reason that access to clean drinking water has long been a human right. Protecting water supplies is also a duty for companies. It is no wonder that investments in clean water can yield good returns.

time to read: 3 minutes | Author: Nico Popp
ISIN: AMERICAN WATER WKS DL-_01 | US0304201033 , Memiontec Holdings Limited | SGXE56008290 , RIO TINTO LTD | AU000000RIO1

Table of contents:


    American Water Works: How valuable water can be

    American Water Works is a classic utility company that operates in more than 45 US states and supplies customers in a district in Canada. The Company takes care of both fresh water and wastewater. Although water supply is less cyclical, American Water Works felt the pandemic: as more people were in their homes during the day, water consumption increased. An acquisition that brought the Company more than 45,000 customers also boosted sales.

    In addition, American Water Works maintains a working relationship with the US military, supplying water to their bases and taking care of their wastewater. However, with a price-earnings ratio (P/E) of around 40, the stock is already expensive. Since the growth potential in North America, where American Water Works is active, also seems limited, the stock is not very promising. However, the Company is solid - the downside risk is limited.

    Memiontec: Clean water, Made in Asia

    Memiontec is a water share with much more growth potential. The Singapore-based Company relies on using various processes, such as technical, chemical and biological processes, to purify water. In addition to the prosperous city-state of Singapore, the most important markets for Memiontec are Indonesia and China. Here, Memiontec takes care of water, wastewater as well as their purification and builds corresponding plants. Memiontec has now been active in this field for 28 years.

    At the end of April 2021, the Company had full order books with a volume of over 90 million Singapore dollars (SGD). Memiontec has increased its dividend by more than 20% each year for the past two years. On the stock market, the Company is currently valued at only around EUR 30 million. Given the growing demand for clean water and Memiontec's experience in Asian countries such as Indonesia and China, the stock is worth considering for speculative investors. Memiontec offers a robust utility business in one of the world's emerging regions and thus could be attractive to various investor groups.

    Rio Tinto: Something still needs to happen here!

    While companies like Memiontec stand for purifying water and turning dirty water back into drinking water in complex processes, companies like Rio Tinto stand for the opposite: Despite all ESG efforts, mining is still a critical industry from a water conservation point of view. Mines generally consume a lot of water and pollute it too. However, large companies, such as Rio Tinto, are increasingly being pushed by the market to invest in sustainability. Over a five-year period, Rio Tinto plans to invest USD 1 billion in climate projects. Around three-quarters of its energy already comes from renewable sources. Operationally, things are also going well for the Company, with sales and profits increasing significantly in the past fiscal year. However, due to fluctuating prices for raw materials, the business remains cyclical - in the current year, the figures are expected to be roughly on a par with the previous year.

    Despite this vulnerability, or precisely because of it, Rio Tinto shines with an excellent balance sheet: an equity ratio of more than 50% and cash and cash equivalents in the double-digit billions speak a clear language. Nevertheless, the question must be allowed why the Company cannot invest these funds profitably and less cyclically. The share is solid and offers an exciting dividend yield of around 4.5%. Precisely because of the good numbers, Rio Tinto could do even more for sustainability and clean water.


    Awareness of clean water is rising. Especially in growth regions, utilities often cannot keep up with population development, where innovative companies are needed. While the US Company American Water Works has little growth potential, Memiontec operates in a booming region in Asia. Although the share is the most speculative of all three stocks presented, it also offers the greatest potential - despite the traditionally solid water-related business.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read